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MS   Mass spectrometry  
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FRAKSI GYNURA PROCUMBENS YANG DIPERKAYA DENGAN ASID 
FENOLIK SEBAGAI AGEN ANTIHIPERLIPIDEMIK DAN ANTIOKSIDA 
BERPOTENSI 
 
ABSTRAK 
 
G. procumbens boleh didapati di kebanyakan negara Asia Tenggara dan daunnya 
digunakan sebagai ubat untuk merawat pelbagai penyakit termasuk hiperlipidemia. 
Objektif kajian ini termasuk pemencilan sebatian penanda, pemiawaian dan analisis 
fitokimia sampel tumbuhan G. procumbens dan penyelidikan kesan antioksida dan 
antihiperlipidemik mereka dalam model tikus akut dan kronik, penentuan tindakan 
mekanisma dan profil toksikologi mereka. Sampel daun G. procumbens telah diekstrak 
dengan 95 % etanol dan difraksinasi kepada tiga fraksi: F1 (air), F2 (50 % metanol) dan 
F3 (aseton). Pemurnian selanjutnya terhadap F2 telah menghasilkan asid fenolik, asid 
klorogenik (CA). Analisis antioksida mendedahkan bahawa F2 mempunyai kandungan 
fenolik tertinggi dan aktiviti antioksida yang kuat. CA juga menunjukkan aktiviti 
antioksida yang kuat setanding dengan piawaian rujukan. Sampel-sampel G. 
procumbens, ekstrak dan fraksi-fraksi dipiawaikan menggunakan asid fenolik (asid 
kafioyilkuinik: CA, 3,4DC, 3,5DC dan 4,5DC) sebagai sebatian penanda dengan kaedah 
RP-HPLC yang disahkan. Analisis fitokimia mendedahkan bahawa, F2 diperkaya 
dengan asid kafioyilkuinik berbanding dengan fraksi-fraksi lain. Kajian 
antihiperlipidemik akut ekstrak, fraksi-fraksi dan CA G. procumbens yang telah 
dipiawaikan menyatakan bahawa S(F2) dan CA mempunyai aktiviti antihiperlipidemik 
yang paling kuat untuk merendahkan tahap TC dan TG dalam tikus hiperlipidemik akut 
diinduksi dengan p-407 (500 mg/kg; ip). Di samping itu, S(F2) juga mengurangkan 
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tahap LDL-C, VLDL-C, AI dan CRI secara ketara selepas rawatan selama 58 jam diikuti 
oleh CA. Oleh itu, S(F2) telah dipilih untuk penyiasatan lanjut menggunakan model 
hiperlipidemik kronik. Rawatan selama lima minggu dengan pelbagai dos S(F2) 
menghasilkan kesan antihiperlipidemik bersandarkan dos, di mana kesan yang paling 
kuat diberikan oleh 500 mg/kg S(F2). Fraksi tersebut didapati merendahkan tahap TC, 
TG, LDL-C, VLDL-C, CRI dan AI pada masa yang sama meningkatkan paras HDL-C 
tikus hiperlipidemik secara ketara. Kedua-dua S(F2) dan CA telah menunjukkan aktiviti 
perencatan pada enzim HMG-CoA reduktase sementara, hanya CA mempamerkan 
aktiviti perencatan sederhana terhadap enzim lipase pankreas. Di samping itu, S(F2) 
menunjukkan keberkesanan bersandarkan dos dimana dos 500 mg/kg menurunkan tahap 
sintesis lipid hati (TC dan TG) dan meningkatkan perkumuhan lipid (TC) dan asid 
hempedu melalui tinja. CA menunjukkan kesan sitotoksik sederhana terhadap MCF-7 
dan Hela, manakala ia adalah selamat pada sel-sel HCT-116 dan Eahy. Sebaliknya, 
S(F2) tidak menunjukkan kesan sitotoksik pada semua sel kanser dan normal. Kajian 
toksisiti akut pada S(F2) menunjukkan bahawa fraksi tersebut adalah selamat dan LD50 
dianggarkan lebih daripada 5000 mg/kg. Kesimpulannya, fraksi bioaktif S(F2) 
berpotensi sebagai agen merendahkan lipid yang boleh menghalang hiperlipidemia dan 
penyakit kardiovaskular dengan mengurangkan tahap lipid serum. 
 
 
 
 
 
xxviii 
 
PHENOLIC ACID RICH FRACTION OF GYNURA PROCUMBENS AS 
POTENTIAL ANTIHYPERLIPIDEMIC AND ANTIOXIDANT AGENTS 
 
ABSTRACT 
 
 
G. procumbens is found in most of the Southeast Asian countries and the leaves 
are used as a folk medicine to treat various illnesses including hyperlipidemia. The 
objectives of the present study include isolation of marker compound(s), standardization 
and phytochemical analysis of G. procumbens plant samples and investigation of their 
antioxidant and antihyperlipidemic effects in acute and chronic rat models, 
determination of their mechanisms of action and toxicological profiles. The leaves of G. 
procumbens were macerated with 95 % ethanol and fractionated into three fractions: F1 
(water), F2 (50 % MeOH) and F3 (acetone). Further purification of F2 yielded a 
phenolic acid, chlorogenic acid (CA). Antioxidant analyses revealed that, F2 possessed 
highest phenolics content and strong antioxidant activities. Likewise, CA exhibited 
potent antioxidant activities that were comparable to reference standards. The G. 
procumbens plant samples, extract and fractions were standardized using phenolic acids 
(caffeoylquinic acids: CA, 3,4DC, 3,5DC and 4,5DC) as marker compounds by a 
validated RP-HPLC method. Phytochemical analysis revealed that, F2 was enriched 
with caffeoylquinic acids compared to other fractions. Acute antihyperlipidemic study of 
standardized extract, fractions and CA of G. procumbens indicated that S(F2) and CA 
had most potent antihyperlipidemic activity on lowering TC and TG levels in p-407 (500 
mg/kg; i.p.) induced acute hyperlipidemic rats. In addition, S(F2) also significantly 
reduced levels of LDL-C, VLDL-C, AI and CRI after 58 h treatment followed by CA. 
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Hence S(F2) was chosen for further investigations in chronic hyperlipidemic model. 
Five weeks of treatment with various doses of S(F2) resulted in dose dependent 
antihyperlipidemic effects, whereby the most potent effect was exerted by 500 mg/kg of 
S(F2). The fraction significantly decreased TC, TG, LDL-C, VLDL-C, CRI and AI 
levels while increased HDL-C level of hyperlipidemic rats. S(F2) and CA showed 
inhibitory effect on HMG-CoA reductase enzyme while, only CA had moderate 
inhibitory activity on pancreatic lipase enzyme. In addition, S(F2) (500 mg/kg) dose 
dependently reduced liver lipids synthesis (TC and TG) and increased the excretion of 
lipids (TC) and bile acids via feces. CA showed mild cytotoxic effects against MCF-7 
and Hela, while it was safe on HCT-116 and Eahy cells. In contrast, S(F2) exhibited no 
cytotoxic effects on all cancer and normal cell lines. Acute toxicity on S(F2) indicated 
that the fraction was safe and LD50 was greater than 5000 mg/kg. In conclusion, S(F2) 
bioactive fraction is a potential lipid-lowering agent which may prevent hyperlipidemia 
and cardiovascular diseases by lowering serum lipid levels. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
Around the world, non-communicable diseases such as cardiovascular diseases, cancer, 
diabetes and chronic respiratory diseases kill 40 million people each year (WHO, 2017). 
Health data gathered from countries around the world revealed that cardiovascular 
diseases remain the leading cause of death with ≈17.7 million deaths annually (WHO, 
2017). In Malaysia, 73 % of total deaths are contributed by non-communicable diseases 
with cardiovascular diseases being the main contributor (NHMS, 2015). There are a 
number of risk factors associated with the development of cardiovascular diseases such 
as hyperlipidemia, obesity, hypertension and diabetes which are caused by unhealthy 
lifestyle factors which include smoking, unhealthy diet and lack of physical exercises 
(Buttar et al., 2005). Among the risk factors, hyperlipidemia plays a significant role in 
inducing atherosclerosis which leads to heart attack, stroke, angina and various types of 
heart and blood vessel disorders, collectively belong to cardiovascular diseases (WHO, 
2017; Kaur et al., 2013). 
 
 Hyperlipidemia is defined as elevated levels of blood total cholesterol (TC), 
triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C) and declining of high-
density lipoprotein-cholesterol (HDL-C). WHO (2017) revealed that hyperlipidemia 
associated diseases cause approximately 2.6 million deaths annually worldwide and the 
prevalence is the highest in Europe with 54 % for both sexes. While in Malaysia, NHMS 
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(2015) revealed that 47.7 % of total population aged above 18 is suffering from this 
condition, which has doubled since 2006 (20.7 %). The incidence of hyperlipidemia is 
known to be one of the main contributors for cardiovascular diseases in Malaysia 
(NHMS, 2015). Despite the availability of various antihyperlipidemic drugs (statins, 
niacin, fibrates, bile acid sequestrants) in the market, many still opt for herbal medicines 
as an alternative. The demand and popularity for herbal medicines in both developed and 
developing countries are due to the presumed minor side effects, good efficacy in 
management of human diseases and their availability at affordable prices (Gunjan et al., 
2015).  
 
Herbs or medicinal plants usually have broad pharmacological activities mainly 
due to their bioactive phytochemicals such as the flavonoids, alkaloids, terpenoids, 
glycosides and lignans. In addition to their medicinal properties, medicinal plants are 
also well known for their antioxidant potential to fight against reactive oxygen species 
(ROS) which is the main contributor to the development of many diseases (Chodak et 
al., 2011). Of interest, a particular attention has been focused on phenolic acids 
especially mono- and di-caffeoylquinic acids due to their extended range of 
pharmacological activities besides their known antioxidant and radical scavenging 
activities (Križman et al., 2007).  
 
Numerous studies on various plants have revealed that consumption of 
polyphenols/phenolic acids rich plants may reduce the risk of cardiovascular diseases 
caused by hyperlipidemia via lipid lowering mechanism (Križman et al., 2007; Inbaraj et 
al., 2010). Moreover, literature have also confirmed that medicinal plants having both 
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antihyperlipidemic and antioxidant properties are better in managing disorders 
associated with hyperlipidemia which are usually accompanied by increased oxidative 
stress (Patil et al., 2014). Studies also have revealed that caffeic acid derivatives such as 
1,3-dicaffeoylquinic acid (1,3DC), 1,5-dicaffeoylquinic acid (1,5DC), 3,4-
dicaffeoylquinic acid (3,4DC), 3,5-dicaffeoylquinic acid (3,5DC) and 4,5-
dicaffeoylquinic acid (4,5DC) possessed better antioxidant potential and displayed 
protective role against cardiovascular diseases nearly tenfold higher than normal mono-
caffeoylquinic acids (Chen et al., 2013; Wang et al., 2009; Inbaraj et al., 2010). 
Considering all the factors mentioned above, it is rationale to investigate a plant that has 
been in existence in the traditional medicinal system for a long time and is used for 
management of various human diseases. 
 
Gynura procumbens (Lour.) Merr from Asteraceae family is locally known as 
‘Sambung nyawa’ or ‘Bai bing cha’ by the Malay and Chinese communities respectively 
(Shwter et al., 2014). This decumbent perennial herbaceous shrub is abundantly 
distributed in South East Asian countries such as Malaysia, Thailand, Indonesia, 
Philippines, China and Borneo (Kaewseejan & Siriamornpun, 2015). Traditionally, the 
leaves of this plant are used to treat ailments such as fever, migraine, inflammation, 
kidney problems, rheumatism, diabetes, high blood pressure, rashes and constipation 
(Kaewseejan & Siriamornpun, 2015; Kaewseejan et al., 2015; Wu et al., 2011). The 
plant is non-toxic and the leaves are still being used as food source by the natives where 
it is generally consumed raw as salad. Several studies have reported that the leaves of G. 
procumbens possessed a vast range of pharmacological activities such as antioxidant, 
antifungal, antiherpes simplex virus, antihyperglycemic, antibacterial, anti-
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inflammatory, antiulcer, anticancer and antihypertensive (Wu et al., 2011; Abrika et al., 
2013; Iskander et al., 2002; Kaewseejan et al., 2012; Mahmood et al., 2010; Mustafa et 
al., 2010; Rahman & Asad, 2013). Bioactive chemical constituents isolated from          
G. procumbens leaves include flavonoids, phenolic acids (gallic acid, p-coumaric and 
ferulic acids), tannins, terpenoids, saponins, alkaloids, coumarins, anthocyanins and 
stigmasterol (Kaewseejan & Siriamornpun, 2015; Rahman & Asad, 2013). 
 
1.2 Problem statement 
Previous studies reported that 95 % ethanolic extract (ethanolic extract) of                    
G. procumbens leaves contained high contents of phenolics and flavonoids (Kaewseejan 
& Siriamornpun, 2015). However, not many studies were carried out to determine the 
classes/individual compounds or fractions of G. procumbens extracts that are responsible 
for its pharmacological activities. Zhang and Tan (2000), first reported on the lipid 
lowering effect of ethanolic extract of G. procumbens in streptozotocin-induced diabetic 
rats. Preliminary findings by Meng (2011) and Saeed (2013) revealed that the ethanolic 
extract of G. procumbens had promising antihyperlipidemic effect by reducing blood 
lipid levels of the acute and chronic hyperlipidemic rat models. However, to date, a 
question still remains on which class(es) of chemical constituent(s) or compound(s) 
is/are responsible for the antihyperlipidemic activity observed by the earlier researchers. 
Meng (2011) has also reported on the isolation of two major phenolic acids from the 
ethanolic extract of G. procumbens, namely chlorogenic acid (CA) and 3,5DC. This has 
created an interest to work on the bioactivity of the fractions of ethanolic extract of G. 
procumbens to evaluate their antihyperlipidemic effects and further investigate the 
possible mechanisms of action and toxicity. 
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1.3 Hypothesis 
Phenolic acid rich fraction is expected to be fractionated from the ethanolic extract of G. 
procumbens using resin column technology. Phenolic acid(s) will then be isolated from 
the bioactive fraction and the isolated compound(s) will be used as marker compounds 
to standardize G. procumbens plant samples. The phenolic acid rich bioactive fraction is 
expected to possess potent antioxidant and antihyperlipidemic activities. Hence, the 
fraction and the isolated compound(s) should be able to cure hyperlipidemia via multiple 
mechanisms such as inhibition of lipid related enzymes, increased secretion of fecal bile 
acids and excretion of lipids. The bioactive fraction and isolated compound(s) are also 
expected to be safe for ingestion. 
 
1.4 Research objectives 
The main objective of the present study is to evaluate antihyperlipidemic activity of 
standardized phenolic acid rich fraction of G. procumbens using animal models and to 
investigate the mechanisms of its antihyperlipidemic action. 
The sub-objectives of present study include: 
1. To fractionate the ethanolic extract of G. procumbens using resin column 
technology. 
2. To isolate and characterize phenolic acid(s) from ethanolic extract of G. 
procumbens. 
3. To evaluate antioxidant activities of ethanolic extract of G. procumbens and its 
fractions and phenolic acid(s).  
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4. To standardize ethanolic extract of G. procumbens and its fractions using 
phenolic acid(s) isolated as marker compounds. 
5. To evaluate antihyperlipidemic activities of standardized ethanolic extract of G. 
procumbens and its fractions and phenolic acid(s) in chemically-induced 
hyperlipidemic rats. 
6. To evaluate antihyperlipidemic activity of standardized bioactive fraction of G. 
procumbens in high fat diet (HFD)-induced hyperlipidemic rats. 
7. To investigate the mechanisms of antihyperlipidemic activity of standardized 
bioactive fraction of G. procumbens and its phenolic acid(s) on: 
a) inhibition of selected enzymes involved in lipids biosynthesis and 
metabolism 
b) removal of excess lipids through bile acids and feces 
8. To investigate the potential cytotoxicity and acute toxicity of the standardized 
bioactive fraction of G. procumbens and its phenolic acid(s).  
The research flow is summarized in Figure 1.1.
  
 
7 
  
 
 
 
 
 
 
 
 
 
 
  
 
Toxicological study 
In vitro 
antioxidant for 
extract, fractions 
& phenolic acid(s) 
HMG-CoA 
reductase & 
pancreatic lipase  
 
TPC 
TFC 
FRAP 
DPPH 
ABTS 
Quantification of 
G. procumbens 
samples from 5 
different 
locations   
Ethanolic extract 
Antioxidant study Phytochemical analysis Antihyperlipidemic study 
Cytotoxicity 
study for 
standardized 
bioactive 
fraction & 
phenolic 
acid(s) 
Acute study 
for 
standardized 
bioactive 
fraction 
P-407-induced 
acute 
hyperlipidemic 
model for 
standardized 
extract, 
fractions & 
phenolic 
acid(s) 
Enzymes 
inhibitory 
activities of 
standardized 
bioactive 
fraction & 
phenolic 
acid(s)  
HPLC 
standardization 
using phenolic 
acid(s) & 
standards   
MCF-7  
Hela 
HCT-116 
Eahy 
 
 
Fractionation & isolation of 
marker compound(s) 
HFD-induced 
chronic 
hyperlipidemic 
model for 
standardized 
bioactive 
fraction  
Mechanisms of 
anti- 
hyperlipidemic 
activity  
Effects on 
lipids & bile 
acids 
excretion 
Figure 1.1: Flow chart of the study 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 The genus Gynura  
The genus Gynura was first described by Cassini in 1825 and so far forty four species 
have been identified globally (Vanijajiva & Kadereit, 2011). Gynura is a perennial 
herbaceous shrub that belongs to Asteraceae-Senecioneae family which is widely 
distributed in tropical countries such as Africa, Southeast Asia, Southern Japan, 
Southern China, Northern Australia and New Guinea (Kaewseejan & Siriamornpun, 
2015). About hundreds of research papers have been published on the phytochemical 
and pharmacological studies of the genus, Gynura. Among the species that have been 
studied are G. angulosa, G. aurantiaca, G. bicolor, G. calciphila, G. crepidioides, G. 
cusimbua, G. divaricata, G. elliptica, G. formosana, G. japonica, G. medica, G. 
nepalensis, G. pseudochina, G. scandens and G. segetum (Vanijajiva & Kadereit, 2011). 
 
2.2 Gynura procumbens (Lour.) Merr. 
2.2.1 Description of Gynura procumbens (Lour.) Merr.  
G. procumbens (Figure 2.1) is an evergreen plant belonging to the Astereceae 
(Compositae) family indigenous to Southeast Asia especially Malaysia, Indonesia and 
Thailand (Bhore et al., 2010). In Malaysia, this plant species can be found growing wild 
or cultivated and has limited distribution at the western part of peninsular Malaysia 
(Keng et al., 2009). The plant has several scientific synonyms such as Cacalia 
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procumbens Lour., Calacia procumbens Lour., G. sarmentosa DC. and Cacalia 
sarmentosa Blume (Mustaffa et al., 2011). Taxonomic classification of G. procumbens is 
shown in Table 2.1. 
 
 
Figure 2.1: Gynura procumbens plant 
 
Table 2.1: Taxonomic classification of Gynura procumbens (Lour.) Merr. 
Domain Eukaryota 
Kingdom Plantae 
Subkingdom Viridiplantae 
Class Spermatophyta 
Order Asterales 
Family Asteraceae 
Subfamily Asteroideae 
Genus Gynura 
Species procumbens 
Scientific name Gynura procumbens 
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G. procumbens is commonly known as sambung nyawa (prolongation of life), 
daun dewa, akar sebiak or kecam akar by the Malays while ‘bai bing cha’ (100 ailments) 
by the Chinese in Malaysia (Tan et al., 2016). The reason why the plant is called 
sambung nyawa and ‘bai bing cha’ is due to the vast range of uses in traditional 
medicine. Preparations of G. procumbens have been utilized traditionally for the 
treatment of skin conditions, kidney problems, rheumatism, hypertension, diabetes, viral 
infection, ringworm infection, constipation, inflammation, eruptive fever, rashes, 
migraine and cancer (Bhore et al., 2010; Mustaffa et al., 2011; Tan et al., 2016).  
 
Even the leaves of this plant have been used extensively in different ways as a 
part of food in different cultures. In Malaysia, the fresh leaves are edible as salad known 
as ‘ulam’, eaten with rice and used as flavoring for food. Meanwhile in Thailand, the 
leaves are either eaten raw or boiled to be used as a garnish in food preparations such as 
curries, salads, soups and entrees. Scientific investigations on the leaves of this plant 
have shown that it’s safe for consumption (Rosidah et al., 2009). 
 
G. procumbens is a fast growing decumbent shrub that can grow up to 10-25 cm 
tall (Keng et al., 2009). The plant is highly branched with hairy leaves arranged 
alternately on hairy stem (Rahman & Asad, 2013; Saiman et al., 2012; Keng et al., 2009; 
Mustaffa et al., 2011). The leaves of this species normally are green in color, succulent, 
hairy on both surfaces, differ in shape either ovate, elliptic or lanceolate, 3.5-8.0 cm 
long, 0.8–3.5 cm wide, with cuneate or rounded base and an acute or obtuse attenuated 
apex (Rahman & Asad, 2013; Li et al., 2015; Keng et al., 2009; Mustaffa et al., 2011). 
The stem of the plant is fleshy and has purple tint. The flowering heads are 1–1.5 cm 
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long, yellow in color, narrow and panicled (Rahman & Asad, 2013). The plant produces 
purple flowers that are tubular and bisexual (Sunarwidhi et al., 2014; Keng et al., 2009).  
 
2.2.2 Chemical constituents of Gynura procumbens (Lour.) Merr.  
In 1996, Sadikun and the co-workers isolated a mixture of sterol and sterol glycosides 
from the leaves of G. procumbens. Flash column chromatography of petroleum ether 
extract, followed by further purification using preparative thin layer chromatography 
(TLC) yielded mixture of β-sitosterol [1] and stigmasterol [2]. In addition, the 
chloroform extract subjected to silica gel column chromatography afforded two more 
compounds 3-O-β-D-glucopyranosyl β-sitosterol [3] and 3-O-β-D-glucopyranosyl 
stigmasterol [4]. The group also isolated a nucleic acid, adenosine [5] and two flavanol 
glycosides, kaempferol-3-O-α-L-rhamnosyl-(1→2)-O-β-D-glucopyranoside [6] and 
kaempferol-3-O-β-D-glucopyranoside [7] (Sadikun et al., 1996). 
 
Two types of di-caffeoylquinic acids, 3,5DC [8] and 4,5DC [9] have been 
identified by Jiratchariyakul et al. (2000) from G. procumbens which was found to 
inhibit the replication of herpes causing viruses. Later, Akowuah et al. (2002) isolated 
four compounds from the n-butanol fraction of petroleum ether extract of G. 
procumbens leaves, namely quercetin-3-O-rhamnosyl (1→6) glucoside [10], 
kaempferol-3-O-rhamnosyl (1→6) glucoside [11], kaempferol-3-O-glucoside [7] and 
quercetin-3-O-rhamnosyl (1→2) galactoside [12]. 
 
High-performance TLC (HPTLC) analysis of G. procumbens methanolic extract 
and its fractions resulted in identification of two phenolics namely, kaempferol-3-O-
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rutinoside [11] and astragalin [7] (Rosidah et al., 2008). Nine types of phenolic acids 
were identified using reverse phase-high-performance liquid chromatography (RP-
HPLC) analysis in the ethanolic extract, ethyl acetate fraction and its sub-fractions 
fractionated using Sephadex LH-20 column chromatography. The phenolic acids 
identified were, hydroxybenzoic acids: p-hydroxybenzoic acid [13], gallic acid [14], 
protocatechuic acid [15], vanillic acid [16], syringic acid [17] and hydroxycinnamic 
acids: caffeic acid [18], p-coumaric acid [19], ferulic acid [20] and sinapic acid [21] 
(Kaewseejan et al., 2015). 
 
The aerial parts of G. procumbens were extracted according to polarity using 
petroleum ether, dichloromethane and ethanol. The ethanolic extract which showed 
virucidal and antireplicative actions against herpes simplex virus-1 (HSV-1) and HSV-2 
upon further purification afforded kaempferyl-3-O-𝛼-L-rhamnosyl(1→6)-𝛽-D-
glucopyranoside [11], 3,5DC [8], kaempferyl glucopyranoside [7], 4,5DC [9], 
kaempferyl-3-O-𝛼-L-rhamnosyl(1→6)-𝛽-D-galactopyranoside [22], CA [23], quercetin-
3-O-𝛽-D-glucopyranoside [24], kaempferol [25], 𝛽-sitosterol [1], stigmasterol [2], 𝛽-
sitosteryl glucoside [3], stigmasteryl glucoside [4] and 1,2-bis-dodecanoyl-3-𝛼-D-
glucopyranosyl-sn-glycerol [26] (Jarikasem et al., 2013). 
 
Phytochemical analysis of the antihyperglycemic active fraction using HPLC 
revealed the presence of kaempferol-3,7-di-O-β-D-glucoside [27], which was shown to 
be responsible for antihyperglycemic activity of ethanolic extract of G. procumbens 
(June et al., 2012). Zhang and co-workers investigated methanol (MeOH) extract of the 
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leaves of G. procumbens which afforded a new sesquiterpenoid, muurol-4-ene-1β, 3β, 
10β-triol [28], two sesquiterpene glycosides, muurol-4-ene-1β,3β,10β-triol 3-O-β-D-
glucopyranoside [29] and muurol-4-ene-1β,3β,15-triol 3-O-β-D-glucopyranoside [30] 
and three known sesquiterpenoids, schensianol A [31], negunfurol [32], and 4 β,10α-
aromadendranediol [33] (Zhang et al., 2014b). 
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[1] β-sitosterol  [2] Stigmasterol 
[3] 3-O-β-D-glucopyranosyl β-sitosterol 
[4] 3-O-β-D-glucopyranosyl stigmasterol 
[5] Adenosine 
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[7] Kaempferol-3-O-β-D-glucopyranoside 
[6] Kaempferol-3-O-α-L-rhamnosyl-(1→2)-O-β-D-glucopyranoside 
[8] 3,5DC 
[9] 4,5DC 
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[12] Quercetin-3-O-rhamnosyl (1→2) galactoside 
[13] p-hydroxybenzoic acid 
[14] Gallic acid 
[10] Quercetin-3-O-rhamnosyl (1→6) glucoside [11] Kaempferol-3-O-rhamnosyl (1→6) glucoside 
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[15] Protocatechuic acid [16] Vanillic acid 
[17] Syringic acid [18] Caffeic acid [19] p-coumaric acid 
[20] Ferulic acid [21] Sinapic acid 
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[26] 1,2-bis-dodecanoyl-3-𝛼-D-glucopyranosyl-sn-glycerol 
[23] CA 
[22] Kaempferyl-3-O-𝛼-L-rhamnosyl(1→6)-𝛽-D-galactopyranoside 
[24] Quercetin-3-O-𝛽-D-glucopyranoside 
[25] Kaempferol 
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[27] Kaempferol-3,7-di-O-β-D-glucoside 
[28] Muurol-4-ene-1β, 3β, 10β-triol 
[29] Muurol-4-ene-1β,3β,10β-triol 3-O-β-D-glucopyranoside 
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[30] Muurol-4-ene-1β,3β,15-triol 3-O-β-D-glucopyranoside 
[31] Schensianol A 
[32] Negunfurol 
[33] 4β,10α-aromadendranediol 
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2.2.3 Pharmacological activities of Gynura procumbens (Lour.) Merr.  
2.2.3(a) Wound healing activity 
Zahra et al. (2011) reported that ethanolic extract of G. procumbens leaves significantly 
healed the wound (2 cm in diameter) created on the dorsal neck of rats. After 14 days, 
wounds treated by ethanol extract and intrasite gel showed signs of wound healing with 
less scars and healed earlier than those treated with vehicle (gum acacia) (Zahra et al., 
2011). 
 
2.2.3(b) Anticancer activity 
In 2012, Nisa and the team conducted anticancer study of G. procumbens ethanolic 
extract in rats model of liver cancer induced using 7,12-dimethylbenz(a) antracene. 
Histopathology results revealed that G. procumbens ethanolic extract (300 mg/kg) 
significantly decreased proliferation of liver cells in cancer induced rats compared to 
untreated group, thus G. procumbens can be used as chemopreventive agent to inhibit 
carcinogenesis (Nisa et al., 2012). 
 
2.2.3(c) Antiulcerogenic activity 
G. procumbens ethanolic leaf extract was investigated for its antiulcerogenic activity at 
dose range of 50-400 mg/kg in absolute ethanol induced gastric lesions in rats. The 
animals treated with plant extracts exhibited significant ulcer protection evidenced by 
reduction in ulcer area and edema compared to untreated ulcer control group (Mahmood 
et al., 2010). 
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2.2.3(d) Cardiovascular activity 
Kaur et al. (2012) reported cardiovascular activity of ethanolic (95 %, 75 %, 50 %, 25 
%, v/v) and aqueous extracts of G. procumbens using rat aorta rings procedure. Aqueous 
extract was found to exhibit effective dose dependent vasorelaxation and negative 
chronotropic and ionotropic effects. Data suggested that cardiovascular activity 
possessed by aqueous extract can possibly be attributed to the high content of 
polyphenolic compounds (Kaur et al., 2012). 
 
2.2.3(e) Ultraviolet (UV) protective activity 
Protective activity of G. procumbens on photoaging skin caused by UV radiation has 
been evaluated by Kim and the team in year 2011 using human dermal fibroblasts. The 
result showed that 20 μg/mL of ethanolic extract of G. procumbens inhibited matrix 
metalloproteinase-1 (MMP-1) and MMP-9 expressions up to 70 % and 73 %, 
respectively. The extract effectively reduced ROS production and showed marked 
inhibitory effect on pro-inflammatory cytokine mediators, interleukin-6 (IL-6) and IL-8 
in human HaCat keratinocyte (Kim et al., 2011). 
 
2.2.3(f) Immunomodulatory activity 
Effects of G. procumbens leaves ethanolic extract on immunocompetent T cells (CD4+ 
T cells, CD4+CD25+ T cells, and B220+ cells) were investigated by Dwijayanti and 
Rifa'I to study its immunomodulatory activity in splenic cells. The result indicated that 
G. procumbens ethanolic extract increased the production of T cells compared to 
control. The study concluded that G. procumbens possessed immunomodulatory activity 
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and only a very minimal dose (0.1 μg/mL and 1.0 μg/mL) was required to promote T 
cell activation (Dwijayanti & Rifa'i, 2015). 
 
2.2.3(g) Antihypertensive activity 
Water extract (300 and 600 mg/kg) of G. procumbens, orally fed via gastric gavage to 
spontaneously hypertensive rats for four weeks showed significant lowering of mean 
atrial pressure and heart rate in dose dependent manner. Significant increase in urine 
flow rate was also observed in treated spontaneously hypertensive rats, hence removed 
excess sodium and water. G. procumbens water extract also showed antihypertensive 
activity by inhibiting pressor responses induced by acetylcholine, phenylephrine, 
methoxamine, angiotensin II, and isoprenaline. Overall, the extract was able to lower 
blood pressure through non selective pathway by stimulating vasodilation, heart 
stabilization and diuretic effect (Kaur et al., 2013). 
 
2.2.3(h) Anti-inflammatory activity 
Water and ethyl acetate fractions of the ethanolic extract of G. procumbens were 
subjected to anti-inflammatory evaluation against ear inflammation induced by croton 
oil. The water fraction did not show any anti-inflammatory effect, while ethyl acetate 
fraction showed good anti-inflammatory activity by inhibiting increase in ear thickness 
due to inflammation. Among its sub-fractions, hexane (inhibition 44.6 %) and toluene 
(inhibition 34.8 %) sub-fractions showed comparable activity to reference drug, 
hydrocortisone (inhibition 35.0 %) (Iskander et al., 2002). 
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2.2.3(i) Antiherpetic activity 
Jarikasem and team worked on antiherpetic effects of G. procumbens against HSV-1 and 
HSV-2. The ethanolic extract of the plant showed virucidal and antireplicative activity 
thus it was further fractionated to afford four fractions: F1 (water), F2 (50 % MeOH), F3 
(MeOH) and F4 (ethyl acetate). All fractions except F1 showed antiherpetic activity 
against HSV-1 and HSV-2. The active fractions contained a mixture of di-caffeoylquinic 
acids, mixture of 𝛽-sitosterol and stigmasterol, mixture of 𝛽-sitosteryl and stigmasteryl 
glucosides and 1,2-bis-dodecanoyl-3-𝛼-D-glucopyranosyl-sn-glycerol, all showed potent 
antiherpatic activity against HSV-1 and HSV-2 (Jarikasem et al., 2013). 
 
2.2.3(j) Antidiabetic activity 
The leaves of G. procumbens were subjected to sequential extraction in aqueous ethanol 
of various percentages (95 %, 75 %, 50 %, 25 %) and tested for antidiabetic activity in 
streptozotocin-induced diabetic rats. In acute study, the extracts lowered fasting blood 
glucose level significantly in diabetic rats; however, the lowering effect was the greatest 
in 25 % ethanolic extract. Furthermore, in sub-chronic study, the 25 % ethanolic extract 
exerted highest fasting blood glucose lowering effect by 49.38 % and 65.43 % on day 7 
and 14 respectively, similar to effect of metformin (7th day: 46.26 % and 14th day: 65.42 
%). In addition, 25 % ethanolic and aqueous extracts suppressed peak fasting blood 
glucose in subcutaneous glucose tolerance test for 90 min, which was comparable to the 
effect exerted by metformin (Algariri et al., 2013). 
 
